Immunotherapy for Melanoma: Jedd Wolchok, MD, PhD, Stanford Cancer Institute Breakthroughs in Cancer

"Immunotherapy for Melanoma: Of Mice, Men, Dogs and Penguins (Oh, My!)," by Jedd Wolchok, MD, PhD. Dr. Wolchok has been a principal investigator in numerous pivotal clinical trials. He helped establish immunotherapy as a standard approach to cancer treatment and was instrumental in the clinical development that led to the FDA approval of ipilimumab and the combination of nivolumab and ipilimumab for advanced melanoma. His research focuses on investigating novel immunotherapies, identifying innovative ways to modulate the immune response to cancer, and uncovering the biological mechanisms that drive treatment response and resistance. His presentation examined how T cell therapies are advancing in the treatment of solid tumors through target discovery, metabolic modulation, and exhaustion resistance. Chapters: Intro: 00:00 - 01:50 Lecture: 01:51 - 54:25 Q&A: 54:26 - 01:03:17 Learn more & Follow: Breakthroughs in Cancer Series: https://med.stanford.edu/cancer/about... Stanford Cancer Institute: https://med.stanford.edu/cancer.html LinkedIn:   / stanford-cancer   Instagram:   / stanford.cancer   X(Twitter): https://x.com/StanfordCancer X(Twitter): https://x.com/SCIDirector #CancerResearch #melanoma #immunotherapy #Oncology #StanfordCancer